3 Micro-Cap Biotech Stocks to SELL

1.) Genitope (Nasdaq: GTOP): Clinical trial results for MyVax likely to disappoint.

2.) Favrille (Nasdaq: FVRL): FavId trial likely to fail.

3.) Pharmacyclics (Nasdaq: PCYC): Xcytrin NDA filed under protest with likely rejection by FDA with PDUFA date of 12/31/07.

October 31, 2007